07 aug: Livigno uden ski…
16 aug: Flytning af pension til Luxembourg – valg af kapitalforvalter og ..
07-08-2012 11:05:00

Xstrata Eyes Cost Savings of $390 Million In 2012

Relateret indhold

LONDON--Anglo-Swiss miner Xstrata PLC (XTA.LN) expects to deliver net real cost savings of around $390 million in 2012 as a mix of higher output levels, lower input costs and greater efficiencies help offset higher costs from lower ore grades and a transition period from old to new mines, the company's chief executive said Tuesday.

Xstrata expects to reduce costs by around $970 million in 2012, Mick Davis told Dow Jones Newswires in a call. About 40% of that will come from increased throughput and productivity, about 30% from more efficient processing and better procurement methods, 17% from lower input costs and the balance from improved energy efficiency.

The savings are partly offset by $580 million of cost headwinds that stem from grade degradation and the transitional nature of the business, Mr. Davis said. Xstrata has faced lower copper grades as it transitions from older mines to newer mines.

"A lot of that [$580 million], a significant part of that is actually found in the first half [of the year] as a result of the transitioning and we have less of that in the second half," he said.

Mr. Davis declined to comment on how shareholders might vote in upcoming Sept. 7 vote on the merger of equals with Glencore International PLC (XTA.LN). Xstrata's second largest shareholder, the sovereign wealth fund Qatar Holding LLC, has called on Glencore to sweeten its offer to 3.25 Glencore shares for every Xstrata share, up from 2.8 at the moment.

"It is now really up to the shareholders to decide whether they want the merger to go ahead on these terms or if they prefer Xstrata to continue as a standalone company," Mr. Davis said, noting that Xstrata had "negotiated a deal in the universe of what was possible at the time. We negotiated a ratio which I said at the time was fair to both companies."

He said that either way, Xstrata is incredibly well positioned to be a major contributor to the combined entity or alternatively have real capacity to add value to shareholders if they decide for it to stand on its own.

Write to Alex MacDonald at alex.macdonald@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

August 07, 2012 05:05 ET (09:05 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo: Lægemiddelkomité anbefaler godkendelse af Ozempic i Europa - NY2

15-12-2017 13:19:21
Novo Nordisk har fået en vigtig anbefaling fra en lægemiddelkomité under de europæiske sundhedsmyndigheder, EMA, der anbefaler GLP-1-håbet Semaglutid godkendt på det europæiske marked.Semaglutid, der skal markedsføres under navnet Ozempic, skal først officielt godkendes af EMA og EU-Kommissionen, før midlet kan ryge på markedet, men en positiv anbefaling fra lægemiddelkomitéen er som oftest også l..

Aktier/middag: H+H til tops mens C20 går i rødt

15-12-2017 11:41:22
Humøret er vrissent på børserne i Europa fredag, og ved middagstid er det danske C20 Cap-indeks ingen undtagelse, da det falder 0,9 pct. til 1121,34 - især trukket ned af Novo Nordisk.Uden for eliteindekset belønnes H+H International dog pænt for et virksomhedsopkøb til 800 mio. kr., der vil løfte selskabets omsætning med en halv milliard.USA SPREDER DÅRLIG STEMNINGDen generelle nedturen følger i ..

Aktier/tendens: H+H køber sig til hovedrolle fra åbningen

15-12-2017 08:23:48
Et stort opkøb fra H+H International kan få opmærksomhed fra åbningen af det danske aktiemarked fredag, hvor investorerne også skal fordøje en sænket anbefaling af Novo Nordisk.Nyhederne falder i et marked, der meget vel kan falde lidt fra åbningen. I USA lukkede S&P 500-indekset torsdag 0,4 pct. lavere efter at have ligget marginalt positivt ved dansk børslukketid.Nedturen, der også viser sig i e..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Torsdagens aktier: Vestas overstrålede alle i grønt eliteindeks
2
Novo/DZ: Sænker anbefaling til "sælg" fra "hold"
3
Vestas/Senator: Aftale afskærmer stort set også vind fra Beat-skat
4
Genmab/Jyske: Kursmålet trimmes til 1600 kr. - NY
5
Novo: Lægemiddelkomité anbefaler godkendelse af Ozempic i Europa - NY2

Relaterede aktiekurser

Glencore PLC ORD USD0.01 362,55 1,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. december 2017 16:47:53
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB1 - 2017-12-15 16:47:53 - 2017-12-15 16:47:53 - 1 - Website: OKAY